Smoking has long been associated with Erectile Dysfunction (ED) and Cardiovascular Disease (CVD). However, little research has explored if there is a similar association among men who use Electronic Nicotine Delivery Systems (ENDS), commonly referred to as e-cigarettes.
In the first population-based study of its kind, researchers from NYU Grossman School of Medicine and Johns Hopkins University School of Medicine published a study in the American Journal of Preventive Medicine that suggests men between 20 and 65 years of age with no prior history of CVD but who use ENDS daily are more than twice (2.4 times) as likely as men who have never used ENDS to report erectile dysfunction.
According to the researchers, since ENDS use seems to be associated with ED independent of age, CVD and other common ED risk factors, ENDS users should be informed about the possible link between ENDS use and experiencing ED—which impacts one in five men over the age of 20 in the United States.
“Given that many people use e-cigarettes as a form of smoking harm reduction or to help them with smoking cessation, we need to fully investigate the relationship between vaping products and erectile dysfunction, and potential implications for men’s sexual health. Our findings underscore the need to conduct further studies to contextualize the e-cigarette use pattern that is relatively safer than smoking,” said Omar El Shahawy, MD, PhD, MPH, assistant professor in the Department of Population Health at NYU Langone and lead author of the study. “Our analyses accounted for the cigarette smoking history of participants, including those who were never cigarette smokers to begin with, so it is possible that daily e-cigarette vaping may be associated with higher odds of erectile dysfunction regardless of one’s smoking history.”
The research team used data from the Population Assessment of Tobacco and Health (PATH) Study, a nationally representative study of 45,971 U.S. adults aged 18 years and older that examines various tobacco use behaviors and health outcomes.
This study was restricted to 13,711 males, 20 years and older, who responded to a question regarding ED. Dr. Tanmik Shah, NYU Langone, the lead statistician and study co-author, examined the association between ENDS and ED in the full sample, as well as in a restricted sample of 11,207 adult males aged 20 to 65 years with no prior CVD diagnosis, while adjusting for multiple risk factors. Respondents were classified as never, former and current (occasional or daily) users. Almost half of the participants were former cigarette smokers, 21% were current cigarette smokers, and 14% used other tobacco products.
Compared to those who never used ENDS, daily users were more than two times more likely to report having ED (2.2 times in the full sample and 2.4 times in the restricted sample). There was a significant association between ENDS use and ED among respondents aged 20 to 65 with normal Body Mass Index and without CVD, suggesting an association of ED with ENDS use among a relatively healthy population.
Within the restricted sample, 10.2% of respondents reported ED. Five and a half percent reported occasional ENDS use while 2.5% reported daily ENDS use. Compared to those who reported never using ENDS, current daily ENDS users were more likely to report ED in both the full and restricted samples. Physical activity was associated with lower odds of ED in both population samples.
One study limitation, according to the researchers, is that the analyses were based on self-reported data on ENDS use and ED status, all of which are subject to misclassification and desirability bias (the possibility that respondents will answer questions based on what they think will be perceived favorably by others). There were also no data indicating whether or not the respondents were taking any medications associated with ED such as antidepressants or beta blockers.
Support for the study was provided by the Empire Clinical Research Investigator Program (ECRIP) form the New York State Health Department.
In addition to El Shahawy, other NYU Langone researchers include Scott Sherman, MD; Tanmik Shah, MPH; Meghan Durr, MPH; Ria Pinjani, MPH. Researchers from the Johns Hopkins School of Medicine include Michael J. Blaha, MD, who is the senior author of this work; Olufunmilayo H. Obisesan, MD, MPH; Albert D. Osei, MD, MPH; Iftekhar Uddin, MD, MSPH and Mohammadhassan Mirbolouk, MD. Additional investigators include Emilia J. Benjamin, MD, Boston University School of Medicine; Andrew Stokes, PhD, Boston University School of Medicine, Tom Loney, PhD, Mohammed Bin Rashid University of Medicine and Health Sciences, UAE.